Blood Cell Growth Patterns for Heart Health After Hodgkin's Lymphoma Treatment

Recruiting at 29 trial locations

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Children's Oncology Group

Disqualifiers: Cardiovascular disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

230 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on how blood cell growth patterns might affect heart health in individuals treated for Hodgkin lymphoma. Some treatments for Hodgkin lymphoma can lead to heart problems later, and the study aims to identify those at risk by examining specific blood cell patterns. Participants will provide blood samples, complete surveys, and undergo heart scans (Magnetic Resonance Imaging) to collect data. This trial suits those who have completed a specific treatment plan for Hodgkin lymphoma and can access heart scans without sedation. As an unphased trial, it offers a unique opportunity to contribute to research that could enhance heart health monitoring for Hodgkin lymphoma survivors.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover how blood cell growth patterns relate to heart health after treatment for Hodgkin Lymphoma. Unlike standard treatments that focus directly on treating the cancer itself, this study takes a broader approach by looking at the long-term effects of cancer treatment on heart health. By using advanced techniques like cardiac MRI and detailed surveys, the trial seeks to provide insights that could lead to better management of heart health in cancer survivors. This could ultimately help tailor treatments to minimize heart-related side effects, improving overall patient outcomes.

Who Is on the Research Team?

Robert J Hayashi

Principal Investigator

Children's Oncology Group

Are You a Good Fit for This Trial?

Inclusion Criteria

Enrolled and completed therapy on AHOD1331.

Not known to have had a primary event (relapse/second malignancy/death). Note: Subjects enrolled and/or treated on AHOD1331 at another institution are eligible if they are now being followed at the current COG institution.

Patient must have access to cardiac MRI at institution where receiving follow-up care and must be able to complete cardiac MRI without sedation.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational Study

Patients undergo collection of blood samples, complete surveys, and undergo cardiac MRI. Medical records are reviewed.

Up to 1 year

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on cardiovascular health and clonal hematopoiesis.

Up to 1 year

What Are the Treatments Tested in This Trial?

Interventions

• Biospecimen Collection
• Clinical Evaluations
• Electronic Health Record Review
• Magnetic Resonance Imaging
• Patient Self Reporting
• Study Blood Sampling
• Survey Administration

How Is the Trial Designed?

Group I: Observational (blood samples, surveys, MRI, record review) Experimental Treatment 4 Interventions

Patients undergo collection of blood samples, complete surveys, and undergo cardiac MRI on study. Patients also have their medical records reviewed.

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials

467

Recruited

241,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+